230 related articles for article (PubMed ID: 28072830)
1. Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study.
QuanJun Y; GenJin Y; LiLi W; YongLong H; Yan H; Jie L; JinLu H; Jin L; Run G; Cheng G
PLoS One; 2017; 12(1):e0169567. PubMed ID: 28072830
[TBL] [Abstract][Full Text] [Related]
2. Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2.
Zhang S; Meng T; Liu J; Zhang X; Zhang J
Medicine (Baltimore); 2015 Jan; 94(4):e445. PubMed ID: 25634181
[TBL] [Abstract][Full Text] [Related]
3. Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
Lue Y; Gao C; Swerdloff R; Hoang J; Avetisyan R; Jia Y; Rao M; Ren S; Atienza V; Yu J; Zhang Y; Chen M; Song Y; Wang Y; Wang C
Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H634-H643. PubMed ID: 29775411
[TBL] [Abstract][Full Text] [Related]
4. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
Della Torre P; Mazué G; Podestà A; Moneta D; Sammartini U; Imondi AR
Cancer Chemother Pharmacol; 1999; 43(2):151-6. PubMed ID: 9923821
[TBL] [Abstract][Full Text] [Related]
5. Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice.
Vijay V; Moland CL; Han T; Fuscoe JC; Lee T; Herman EH; Jenkins GR; Lewis SM; Cummings CA; Gao Y; Cao Z; Yu LR; Desai VG
Toxicol Appl Pharmacol; 2016 Mar; 295():68-84. PubMed ID: 26873546
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel.
Della Torre P; Imondi AR; Bernardi C; Podestà A; Moneta D; Riflettuto M; Mazué G
Cancer Chemother Pharmacol; 1999; 44(2):138-42. PubMed ID: 10412948
[TBL] [Abstract][Full Text] [Related]
7. Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice.
Saadane N; Yue P; Alpert L; Mitmaker B; Kirby GM; Chalifour LE
Can J Physiol Pharmacol; 2001 Jun; 79(6):533-44. PubMed ID: 11430591
[TBL] [Abstract][Full Text] [Related]
8. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
9. [Prevention against and treatment of doxorubicin-induced acute cardiotoxicity by dexrazoxane and schisandrin B].
Hu KY; Yang Y; He LH; Wang DW; Jia ZR; Li SR; Tian W; Mao J; Li XJ; Zhang W
Yao Xue Xue Bao; 2014 Jul; 49(7):1007-12. PubMed ID: 25233631
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity.
Liu H; Wang H; Xiang D; Guo W
Mini Rev Med Chem; 2017; 17(1):44-50. PubMed ID: 27337969
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of tetrandrine on doxorubicin-induced cardiotoxicity in rats.
Xu M; Sheng L; Zhu X; Zeng S; Chi D; Zhang GJ
Tumori; 2010; 96(3):460-4. PubMed ID: 20845809
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Al-Harbi NO
Toxicol Mech Methods; 2016; 26(3):189-95. PubMed ID: 26899300
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain SM; Whaley FS; Gerber MC; Weisberg S; York M; Spicer D; Jones SE; Wadler S; Desai A; Vogel C; Speyer J; Mittelman A; Reddy S; Pendergrass K; Velez-Garcia E; Ewer MS; Bianchine JR; Gams RA
J Clin Oncol; 1997 Apr; 15(4):1318-32. PubMed ID: 9193323
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL
Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
[TBL] [Abstract][Full Text] [Related]
16. Activity of dexrazoxane and amifostine against late cardiotoxicity induced by the combination of doxorubicin and cyclophosphamide in vivo.
Bjelogrlic SK; Lukic ST; Djuricic SM
Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):228-38. PubMed ID: 23692343
[TBL] [Abstract][Full Text] [Related]
17. Dexrazoxane Alleviated Doxorubicin-Induced Nephropathy in Rats.
Hu H; Xie C; Weng Z; Yu P; Wang Y; Shan L
Pharmacology; 2022; 107(3-4):206-215. PubMed ID: 35021174
[TBL] [Abstract][Full Text] [Related]
18. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
19. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity.
Koleini N; Kardami E
Oncotarget; 2017 Jul; 8(28):46663-46680. PubMed ID: 28445146
[TBL] [Abstract][Full Text] [Related]
20. Candidate early predictive plasma protein markers of doxorubicin-induced chronic cardiotoxicity in B6C3F
Desai VG; Lee T; Moland CL; Vijay V; Han T; Lewis SM; Herman EH; Fuscoe JC
Toxicol Appl Pharmacol; 2019 Jan; 363():164-173. PubMed ID: 30517846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]